Results Healthcare advises Bridgepoint on its acquisition of PharmaZell

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Buy Side
Feb 2020
has acquired

Results Healthcare is pleased to announce that it has provided transaction advisory support to Bridgepoint on its acquisition of PharmaZell.

PharmaZell, a leading independent manufacturer of niche active pharmaceutical ingredients (APIs), was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Results Healthcare was selected to support on this transaction due to its specialist team and exceptional track record in the pharmaceutical manufacturing sector.

PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs, and enjoys leading industry positions in several products that treat respiratory, inflammatory and liver diseases driven by changing lifestyle habits. Many of the Company’s products require special handling procedures and/or technologies. Headquartered in Raubling (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy and India with over 900 employees globally.

The global market for small molecule APIs is estimated at over $70bn and growing continuously, driven by rising health standards and increasing drug consumption in emerging markets. In addition, the trend to outsourcing continues driven by cost optimisation and streamlining initiatives by the pharma majors.

This is Results Healthcare’s second transaction in the API manufacturing space in the last 12 months, after the acquisition of Sterling Pharma by GHO.

In Bridgepoint we have found a partner who understands our business and who will work with us to help us realise our ambitions for further growth.

Dr. Oliver Bolzern

CEO, PharmaZell

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to